Trials / Recruiting
RecruitingNCT06589765
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with dapagliflozin in subjects with type 2 diabetes mellitus with inadequate glycemic control using metformin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-7535 tablet | HRS-7535 tablet |
| DRUG | dapagliflozin tablet | dapagliflozin tablet |
Timeline
- Start date
- 2024-09-27
- Primary completion
- 2026-02-18
- Completion
- 2026-07-18
- First posted
- 2024-09-19
- Last updated
- 2025-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06589765. Inclusion in this directory is not an endorsement.